Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion

Gerald Batist, Raymond W. Klecker, Hiremagalur N. Jayaram, Jean F. Jenkins, John Grygiel, Daniel C. Ihde, Joyce L. Eddy, Robert L. Fine, Ian G. Kerr, Jerry M. Collins

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, TCAR) is a synthetic C-nucleoside that demonstrated significant in vivo activity against a variety of animal tumors as well as in vitro activity against human tumor-derived cell lines. Thirteen patients were treated with TCAR administered as a 5-day continuous infusion in this Phase I trial. Seventeen complete cycles were administered in three dose levels ranging from 550 to 1450 mg/M2. Dose-limiting toxicities were myelosuppression and neurotoxicity including severe lethargy. Other toxicities including superficial skin peeling, myalgias, and tearing were seen at all doses. One patient had chest pain on day 4 resulting in stopping the drug, however, there was no evidence of cardiac or pericardial disease. Uric acid levels rose within one day in the absence of allopurinol treatment. There were no treatment related deaths. HPLC measurement of drug levels demonstrated steady-state plasma levels during the infusion, and a half-life following the infusion of 7.7 ± 0.6 hours. Minor abnormalities in renal function were associated with dramatic changes in pharmacokinetics and toxicity. No clinical responses were observed in this trial.

Original languageEnglish (US)
Pages (from-to)349-355
Number of pages7
JournalInvestigational New Drugs
Issue number4
StatePublished - Dec 1 1985

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion'. Together they form a unique fingerprint.

Cite this